96 related articles for article (PubMed ID: 20682013)
1. Td92, an outer membrane protein of Treponema denticola, induces osteoclastogenesis via prostaglandin E(2)-mediated RANKL/osteoprotegerin regulation.
Kim M; Jun HK; Choi BK; Cha JH; Yoo YJ
J Periodontal Res; 2010 Dec; 45(6):772-9. PubMed ID: 20682013
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
4. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
5. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
7. Local osteoprotegerin gene transfer to periodontal tissue inhibits lipopolysaccharide-induced alveolar bone resorption.
Chen R; Kanzaki H; Chiba M; Nishimura M; Kanzaki R; Igarashi K
J Periodontal Res; 2008 Apr; 43(2):237-45. PubMed ID: 18086145
[TBL] [Abstract][Full Text] [Related]
8. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
9. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
13. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
14. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
18. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
20. PEDF regulates osteoclasts via osteoprotegerin and RANKL.
Akiyama T; Dass CR; Shinoda Y; Kawano H; Tanaka S; Choong PF
Biochem Biophys Res Commun; 2010 Jan; 391(1):789-94. PubMed ID: 19945427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
